<SEC-DOCUMENT>0001193125-26-249726.txt : 20260601
<SEC-HEADER>0001193125-26-249726.hdr.sgml : 20260601
<ACCEPTANCE-DATETIME>20260601073011
ACCESSION NUMBER:		0001193125-26-249726
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260601
DATE AS OF CHANGE:		20260601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39103
		FILM NUMBER:		261047168

	BUSINESS ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(267) 759-3100

	MAIL ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d71098ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&#8195;) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of registrant as specified in its charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g71098g0531201631859.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2929 Arch Street, Suite 600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Philadelphia, PA 19104 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENT TO PROXY STATEMENT DATED APRIL&nbsp;28, 2026 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE 2026 ANNUAL MEETING OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To be held
June&nbsp;9, 2026 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;28, 2026, Cabaletta Bio, Inc. (the &#8220;<U>Corporation</U>&#8221;) filed a definitive proxy statement (the
&#8220;<U>Proxy Statement</U>&#8221;) for its 2026 Annual Meeting of Stockholders (the &#8220;<U>Annual Meeting</U>&#8221;), to be held on Tuesday, June&nbsp;9, 2026, at 9:00 a.m. Eastern Time. You may participate in the Annual Meeting, including
casting votes and asking questions, by accessing a live webcast at <I>www.proxydocs.com/CABA. </I>This supplement (this &#8220;<U>Supplement</U>&#8221;) to the Proxy Statement amends and supplements the Proxy Statement as filed and should be read in
conjunction with the Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Supplement to the Proxy Statement is being filed on or about June&nbsp;1, 2026, and should be read in
conjunction with the Proxy Statement. Except as described in this Supplement, the information provided in the Proxy Statement continues to apply. To the extent that information in this Supplement differs from or updates information contained in the
Proxy Statement, the information in this Supplement is more current. The information provided herein may be deemed &#8220;additional soliciting materials&#8221; within the meaning of the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Removal of Proposal 3 for Stockholder Consideration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;31, 2026, the Board of Directors of the Corporation (the &#8220;<U>Board</U>&#8221;) determined not to seek stockholder approval of the Corporation&#8217;s Proposal 3, which was described in the Proxy Statement as a proposal to approve an
amendment to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, and has withdrawn Proposal 3 from the agenda for the Annual Meeting. All other proposals presented in the Proxy Statement remain on the agenda for the Annual Meeting.
Accordingly, any information contained in the Proxy Statement regarding Proposal 3 should be disregarded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon review and careful consideration with
further discussions with management and its advisors, the Board has determined to withdraw Proposal 3 from stockholder consideration for the upcoming Annual Meeting. Notwithstanding the foregoing, the Corporation intends to continue to evaluate its
equity compensation program and reserves the right to propose an amendment to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan at any point in the future. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record date for determining the stockholders entitled to notice of, and to vote at, the Annual Meeting
has been set and remains April&nbsp;20, 2026. As a result of the removal of Proposal 3 from stockholder consideration at the Annual Meeting, the Corporation notes the following important matters regarding voting: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Corporation will not make available or distribute, and you do not need to sign, new proxy cards or submit new
voting instructions solely as a result of the removal of Proposal 3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any proxy card or voting instructions received in the future for Proposals 1, 2, 4, 5, and 6 will be valid.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proxy cards or voting instructions received with direction on Proposal 3 will not be voted on Proposal 3.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proxy cards or voting instructions received and providing direction on the remaining proposals to be considered
at the Annual Meeting (i.e., Proposals 1, 2, 4, 5, and 6) will remain valid and will be voted on as directed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If you already submitted a proxy card or voting instructions, you do not need to resubmit proxies or voting
instructions with different directions, unless you wish to change votes previously cast on the remaining proposals. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional
Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the solicitation of proxies, the Corporation filed the Proxy Statement and definitive form of
proxy card on April&nbsp;28, 2026 with the U.S. Securities and Exchange Commission (the &#8220;<U>SEC</U>&#8221;). THE CORPORATION&#8217;S STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE PROXY STATEMENT, THE ACCOMPANYING PROXY CARD, ANY AMENDMENTS OR
SUPPLEMENTS THERETO AND ANY OTHER RELEVANT SOLICITATION MATERIALS FILED BY THE CORPORATION WITH THE SEC IN THEIR ENTIRETY BEFORE MAKING ANY VOTING OR INVESTMENT DECISION BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION. Stockholders can obtain
copies of the Proxy Statement, any amendments or supplements to the Proxy Statement and other documents filed by the Corporation with the SEC for no charge at the SEC&#8217;s website at <I>www.sec.gov</I>. Copies are also available at no charge on
our investor relations website at<I> www.cabalettabio.com/investors</I>. In addition, this Supplement and the Proxy Statement are available at<I>&nbsp;www.proxydocs.com/CABA</I>. The Proxy Statement, copies of other solicitation materials and these
other reports the Corporation files with the SEC can also be obtained at no charge by writing to our Corporate Secretary at Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g71098g0531201631859.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g71098g0531201631859.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  G 4<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[P_:7_:6T
M#]F_P>NH7Z_VAK=YN33M)1]K3L.K,?X47(R?< >WRCH'PG_:'_;"B7Q!XN\7
MS^!/"=W\]MI\(>-7C/0K;(R[E]&D;=]0:/AAH"?MB?MH^+?%.O+]N\'^$)?+
MM+23F)PDC);H1Z,4DE([D8Z&OT050BA5 50,  < 5R).NVV_=/IZE2.41C3I
M13K-)MM7Y;[)+OW9\&-_P2]FTM?M6A_%+4+'55^99S9D9;ZK("/KDUFVOQF^
M-W[&'B2PTWXI&7QSX#N9!%'JX<S21C_9F;YMP'.R3(."%/4U^@U<[X_\!:'\
M3?">H>'/$5DE_I5[&4EB;@CT93U5@>01R"*;H*.M/1F$,WJ5GR8U*I!^2NO-
M-6U+7A+Q9I7CGPWI^OZ'>1W^E7\0F@N(SPRG^1!R"#R""*V*X+X5_"?PU\!/
M!]QH^@R7%KHD<CW;+>W32K"2!N(+GY1QG'3K7RA\0?VROB%\8/'%WX.^ NC&
MYAMF*3:Y)$'W8."PW?*B=<$\G&1Z5I*IR)<VYQ4<%+%U9K#OW%UEHDO,^[**
M^!IO"/[9G@^W.LIXAL]:9!YC:>MPD[,/0(Z ?K7K'[+_ .V5'\7-9F\%^,M-
M'AKQW;94V[ I'<E?O!0W*OWV]^U*-9-V:MZFM7+*D*;JTIQFEORN]O5'JO[3
M-S-9?L]?$:>WE>">/0;QDDC8JRL(FP01T->9_P#!//4[S5_V<+&XOKN:]N#J
M%P#+<2%VP-O&2<UZ/^U'_P FY?$K_L 7G_HIJ^#?@+^UUJ'PN^!FB^ O NB/
MX@\=WU[.RH8RZ0*VT*=H^\W!/H,<UG4FH54Y=CNP>%J8O+YPI*[YU\E;J^Q^
MH=%? X\$_MFZ[ -9;Q)9Z?(PWC3S<I$P_P!G8J;?PS6S\)?VT?&7@3QW;^ _
MCKH_]DWL[".#61$(U))P"X7Y64\?,O3/-4JZO[R:.664U'%NC4C-K=1=W_P3
M[?HID<BS1JZ,'1@&5E.01V(KP3]J3]K'2?V>M-M[&UMAK?B^_'^AZ8A.%'0.
M^.<9Z <FMY24%=GET*%3$U%2I*[9[]17Y_Z98?MC?%B :Y#JEMX6M9AYD-G-
M(MJ0IY VJI/_ 'US4VF?M5?&;]G#Q-9:5\;-$&J:!<N(UU>VC7*CU5U #8]&
M&:P]NMVFD>L\HJ.\:52$I+[*>OR[GWU7PYJ6NZDO_!2>STX:A="P-BI-J)F\
MK/EG^'.*^S_#/B73?&&@6.M:/=)>Z;>Q":">,Y#*:^(M3_Y2<V7_ %X+_P"B
MS16?PV[H65QM*NI+50D?>-%5=4U2UT73KF_OITM;.VC,LLTAPJ*!DDFOA3QE
M^UW\4OCOXOO/#7P)T9TTRV8I+K4L0);MNW-\J#TQ\U:3J*&YPX3!5<6WR626
M[>B7S/O6BOS^E\(_ME^ XCK2Z_!KXC&]K!;I;DD=QL= /R->V?LO_M@6_P 9
M;Z?PIXIT_P#X1OQW9@B6R<%4GQU* \@CNOY5,:R;Y6K/S.FMEDZ=-U:4XSBM
M^5WMZHWOVWM1N]*_9L\5W-C<S6=RB1[9H)"CK\PZ$<BK?[&=_=:G^S;X+N;R
MXEN[F2UR\T[EW8[CU)Y-9G[=O_)L/B[_ '(__0Q7RW^SM-^U&OPT\,#P;/IJ
M^#-J_9EFMX&?RMW.2R$^O>LI2Y:VU]#NP^&6(RRW-&-I[R=NA]%?\%#M6OM%
M_9PO;G3[R>QN!J-LHFMI6C?!W9&00:]/_9MNY[[X"^!+BYFDN)Y-*A9Y96+,
MQQU)/)KQ_P#X*(^?_P ,L2_:<?:?MUGYN.F_#9_7->2? 6;]JD>%O! TJ?3!
MX(V6XB5[>W,GV/<,\E-V=N>^:'/EJO1O0=/#>WRR/O1C:;W=KZ+8_06BO'_V
MCOVDM"_9U\(IJ&I+]NUBZ!2QTR-L-,WJ?11W/X5\M:1K7[7/Q[A_MS1Y[?P;
MHT_SVT,K"U!3MCY2Y_X%6TJJB^5*[/-P^75*]/VTI*$.\G:_IW/T%HK\_9OV
M@/VAOV7]2M7^*>E1>*?"LCA'OK<*VS_=E4 Y_P!X8K[;^''Q%T/XJ^$+#Q)X
M>NQ=Z=>)N4_Q(>ZL.Q!X(IPJ*;MLR,5@*N%BJC:E![-.Z.GKX(_X*+7FL2_$
M_P"&VC:9K5[HZZFHMGDM9G0 O.$W%5(W8S7WO7P3_P %!/\ DO'P<_Z^8?\
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ML!G70K\3SH!G]VZ[23[#O6U\"/@'\!OB]\+=!\1V7@C2KF2:V1;H>9)N2=0
MX8;^#G)_&M'S^V?+;;J<5-X9973]MS6YG?EMOTO?RV.J_P"&Z_@O_P!#=%_W
M[:OD']K;XQ_#G4_B1X/^)'PUUR)_$ME=*+];="AD12"&/J<96OM3_AC/X*_]
M$^TS_ON7_P"+KQOXF^%_V:?AE\1=%\$7/PYAU3Q#JA14MM/$DABW-@;_ -YQ
MZ_2BHJCC:30\!5P-.MS8>%23L[KW;-6UOY'>_MG:G_;7[(FN:AC;]KL[>?'I
MNVM_6MS]B7_DV/P1_P!>G_LQK,_;>LHK#]E3Q/:VT0AMX+>*..(<A$5@ /P%
M:'[$,J2_LQ^"=C!MML5.#T.X\5HOXWR."5O[*TV]I_[:<E_P4@_Y-FOO^PE;
M?^S5ZI^S'_R;[X!_[!$/\J\L_P""CZEOV9K_  ,XU&V)_P#'J]1_9>E2?]GG
MX?NC!E.D0\CZ4U_&?H*I_P BJG_C?Y(^3-)T:/\ :4_;[UX:Z/M>@>$ RP6C
M\QL8R%08]"V6/N*_0&.-(HU1%"(HP%48 'I7Y_>#-9B_9]_X*!>*+/76%GI7
MBLL;:YDX3,A#1\].N1]<5^@:D, 1R#T-*A]J^]RLWOS45'X.2-ONU_'<Q_%_
MA/2_'/AK4-"UFU2\TZ]B:&6*09X(ZCT(Z@U\2?L!WU]\.?C/\3OA3/.TUCI]
MP\L"L>$='*,1]1M_*ON+Q'XAL/"FAWVL:I<I::?91--/-(<!549-?GE^PQXR
M'Q#_ &P?B!XE5=B:I;W-TJ^@:92*55I5(=R\OC.>"Q2?PI)_.Y^C]?GS_P %
M)M-DUKXL?"_3X9S:RW8$"3KUC9IPH8?3.:_0:O@G_@H)_P EX^#G_7S#_P"E
M2UV1W/G'L:7_  P!XWEM^/B_J/S+T+28_G7CGB/X%>._V*_'6F?$>_M;#QWH
MUO,%ENY%9S&6[G=RK>C>M?J';_ZB/_='\J\C_:ZU+2M-_9S\<'5WC6WEL&BC
M60CYIB1Y8 [G=@_A0FQ61W7PV\?Z9\4? ^D>*-'<O8:E LR ]4/\2GW!R#]*
M^-_^"=/_ "5;XV?]?-O_ .C;FO3_ /@G/!?0_LTZ8;L,('O;IK;=_P \_,.<
M>V[=7F'_  3I_P"2K?&S_KYM_P#T;<T=P[$?[8(N/C5^U?\ #CX2O.Z:(@2Y
MNXD.-[-NDD/U\J, >F37W)HFBV/AS2;33--M8[.PM8UBA@A7:J*!@ "OA;]K
M&Z?X*_MF_#GXFW<;#0[F-(9[@#A" \,OY1R*U?=]A?V^JV-O>6DR7%K.@DBE
MC;*NI&00?I0]D-$D\$=U!)#-&LL4BE71QE6!Z@BO@7X<Z6/V</\ @H)=^#])
M)M_"_BN!G2U!^2,/$TJ8'^S(CH/9J^_68(I9B%4#))/ %? ?A358_P!H/_@H
MJWB#13]J\.^$[=D-XG*.(XFC!!Z<S2DCU S0NH,^_:***D9PWQB^#OAKXX^"
M[GPWXFM3/:R?/#<1\36TH'$D;=B/R(X.:^'[SP1^T+^Q-'</X7U>Q\6> (W+
M1QWLBF.,'L8G=71NO$;%>_6BBN>K!-<^S/;RW%U(36&DE*$GJFKKU79F59_\
M%'/BWXSF_L;0/"V@1:O(?+$C%F ;IP&D4#\2:[OP#^Q=\0?C5XOM?&/Q\\0/
M<P1D21:%!.KLPZA"8_W<2'C.PDGN0>:**YJ"=97J.]CZ'-YQRIJ&#@H.2WMK
M\F]C[A'A[2QX?_L,6%NNC_9_L@LA&/*\G;MV;>FW'&*^#?&_[-/Q1_94\6ZE
MXS^"FJ1W?AB<F2ZT>\F0>4N<[75R!(H[,I#@''J245UU(*2OU1\M@<94P]3E
M5G&=DT]4SG++]N7X\_$NY'A?PWX<T&TUZ?\ <^?"0&5NF4\R78#]<UD?%']A
M7QU9_#E_%6M7K>*?B3JNI1M<PK=H$MXBK%MTCE0[9"CC@ 8&>Q17'3A[:+<W
M<^JQ>)_LS$0IX2$8IV;TU?E>^Q^BWPML)](^&7A&PNT\JZM='LX)H\AMKK"@
M89'!P0>E?,G[2/['.N:AXW'Q.^$&IKH/C.-O.N+,2"%+E^[HQ^4,1P5;Y6[X
MYR45W2IQG'E9\C0QE7"UG5I];W71KLUV/&KC]O/XZ>%+K_A&=6\,^'YO$$9\
MGSGZENF6"2[2?H0*[+X:?LJ?$3]H/QO8>/\ XYZFC:;#B6ST2WF5Q(N<A<1D
MK&GKR6/?UHHKBI1]K)J;ND?4YA66 HPGA81A*:U:6J].Q]X6UO#9V\4$$:PP
MQ($CC0855 P !V %?.7[6'[(UO\ '9+7Q%X>O5T+QUIP'V:]R52< Y5'9>00
M>C#I117=*"FN61\AA\15PM15:3LT?-=Y^UW^T%\ '7POXRT;1]7O( (XKJ[D
M5Y7'0%FBDPWX@'UK5T7X3?&G]M?4;#5_B-J5KX?\!POYJ6.GR+B7'9(U9CG_
M &I#QV%%%<,8N<W"3;2/L<36CA<)3Q="G&-2?5+;T['H?[!7P;U_X3>,?B+'
MJFFFPTV:?R[%C<1REXUD;;G8Q(^7'7%6=0^%OB:7_@H!:>,%TX'PZMFJ&[\^
M/@[",;-V[]***W5-*,5V9XL\=5EB:M5I7E&S^Y'UOKFBV'B31[S2]2MH[NPO
M(FAG@E&5=",$&O@7QC\ /BU^R#X@U+Q3\(=6BU+P=,QEN-*O94Q"/[KH[*'
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C[HB74=3=-KW,@'  _A1<G"Y[D]2:**&^@D>LY%%%%24?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
